The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ... as a few other pharma companies like Eli Lilly ...

Meanwhile, pharma products also generate non-degradable waste ... that is known to adversely affect ecosystems. Astellas, Eisai, Daiichi Sankyo, and Takeda said their new initiative aims to ...

A partnership between Eisai ... effort by the pharma group to develop an ‘ecosystem’ to support patients. The alliance, first formed in 2022, envisages a series of insurance products ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.